B/F/TAF治疗HIV感染者病毒学失败的相关因素:预存突变与耐药风险
基于ANRS-CO3-AquiVIH-NA队列636例经治HIV感染者,分析启动B/F/TAF后病毒学失败(VF)的相关因素。基线病毒学抑制者无论有无预存耐药突变均维持较高病毒学成功率,而基线未抑制者VF风险显著升高(HR 9.53)。VF时新发耐药突变罕见。
要点
- 基线病毒学抑制者启动B/F/TAF后病毒学成功率较高,有无预存突变者分别为86.4%与92.8%。
- 病毒学失败时新发耐药突变少见,66例中仅6例出现。
核心结论
- 病毒学抑制的HIV感染者启动B/F/TAF后无论有无预存耐药突变均能维持病毒学抑制,但未抑制者维持程度较低。
- 病毒学失败时新发耐药突变罕见。
研究设计与样本
- ANRS-CO3-AquiVIH-NA队列中2018至2021年启动B/F/TAF的经治HIV感染者636例,按基线病毒载量分层为病毒学抑制(VL<50 copies/mL)和未抑制(VL>50 copies/mL)。
- 预存耐药突变依据累积基因型耐药检测按ANRS算法判定,采用Cox比例风险模型分析病毒学失败相关因素。
主要发现
- 636例中82.7%基线病毒学抑制,23.1%存在至少一种B/F/TAF组分的预存耐药突变(抑制者20.9%,未抑制者33.6%),其中M184I/V突变占89.1%。
- 无预存突变者病毒学成功率为92.8%,有预存突变者为86.4%。
- 66例基线有基因型耐药检测且发生病毒学失败者中,6例(未抑制者2例,抑制者4例)出现新发耐药突变。
- 病毒学失败后56/66例(84.8%)维持B/F/TAF方案,其中40/56例(71.4%)末次访视时VL<50 copies/mL。
临床怎么用
- 对于病毒学抑制的经治HIV感染者,即使存在预存耐药突变,B/F/TAF仍可维持较高病毒学抑制率。
- 基线病毒学未抑制者启动B/F/TAF后病毒学失败风险较高,需加强监测。
- 病毒学失败后部分患者维持B/F/TAF仍可获得病毒学抑制,但需个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We investigated, in a real-world setting, virological factors associated with virological failure (VF) after bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) initiation in people with HIV (PWH) with and without pre-existing drug resistance mutation (PRM) and the emergence of new resistance mutations at virological failure. METHODS: Treatment-experienced PWH from ANRS-CO3-AquiVIH-NA cohort starting B/F/TAF between 2018 and 2021 were stratified depending on their baseline viral load (VL): virologically suppressed (VS; VL <50 copies/mL) and virologically unsuppressed (VU; VL >50 copies/mL). PRM were identified using cumulative genotypic resistance tests (GRT) according to the ANRS algorithm. Factors associated with VF were analysed using a Cox proportional hazards model and survival curves. RESULTS: Among the 636 PWH with available GRT results, 82.7% were VS at B/F/TAF initiation. PRMs to at least one component of B/F/TAF were present for 23.1% of participants (20.9% VS and 33.6% VU), with the M184I/V mutation identified in 89.1% of cases (88.2% in VS and 91.9% in VU). Virological success was higher for those with no PRMs (92.8% no PRM vs 86.4% with PRM). VU PWH had a higher risk of VF [HR 9.53 (5.54-16.40)]. Among the 66 PWH with baseline GRT experiencing VF, new resistance mutations were selected for six (two VU and four VS). After VF, B/F/TAF was maintained for 56/66 (84.8%) participants, of whom 40/56 (71.4%) had a VL <50 copies/mL at their last visit. CONCLUSIONS: Virological suppression was maintained in VS PWH regardless PRMs but to a less extent in VU PWH. Emergence of new resistance mutation occurred rarely in the case of VF.
引用
- Bellecave P, Peyrouny-Mazeau A, Leleux O, et al. Factors associated with virological failure in people with HIV treated with bictegravir/emtricitabine/tenofovir alafenamide. Impact of pre-existing mutations and risk of resistance emergence. ANRS-CO3-AquiVIH-NA cohort. J Antimicrob Chemother. 2026. PMID: 42599770. doi:10.1093/jac/dkag278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。